Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
View/ Open
Date
2012-12-15ICR Author
Author
O'Connor, JPB
Jayson, GC
Type
Journal Article
Metadata
Show full item recordAbstract
The management of solid tumors has been transformed by the advent of VEGF pathway inhibitors. Early clinical evaluation of these drugs has used pharmacodynamic biomarkers derived from advanced imaging such as dynamic MRI, computed tomography (CT), and ultrasound to establish proof of principle. We have reviewed published studies that used these imaging techniques to determine whether the same biomarkers relate to survival in renal, hepatocellular, and brain tumors in patients treated with VEGF inhibitors. Data show that in renal cancer, pretreatment measurements of K(trans) and early pharmacodynamic reduction in tumor enhancement and density have prognostic significance in patients treated with VEGF inhibitors. A weaker, but significant, relationship is seen with subtle early size change (10% in one dimension) and survival. Data from high-grade glioma suggest that pretreatment fractional blood volume and K(trans) were prognostic of overall survival. However, lack of control data with other therapies prevents assessment of the predictive nature of these biomarkers, and such studies are urgently required.
Collections
Subject
Animals
Humans
Neoplasms
Glioma
Carcinoma, Hepatocellular
Carcinoma, Renal Cell
Liver Neoplasms
Brain Neoplasms
Kidney Neoplasms
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Treatment Outcome
Tumor Burden
Biomarkers, Tumor
Research team
Quantitative Biomedical Imaging
Language
eng
License start date
2012-12
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, 18 (24), pp. 6588 - 6598
Publisher
AMER ASSOC CANCER RESEARCH